knowledge -WSS

knowledge

author：explore 2025-09-30 01:03:08 - browse：1898

Editor’s note: A recording of the event is embedded below.

Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. market over the past year. What has that meant for insurance coverage and the way drugmakers are marketing these medicines? Join leading experts to discuss the impact on the industry and patients.

Sponsor introduction

Thomas Newcomer, vice president and head of U.S. market access, Samsung Bioepis (sponsor)

Featured speakers

Chris M. Brown, president, McAteer
Michael Gonzales, independent health care consultant, Michael Gonzales, LLC; former national and regional account director, AbbVie
Fran Gregory, MBA, PharmD, vice president of emerging therapies, Cardinal Health
Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)

WSS

Senators: Long

It's been 20 years since Dolly the sheep. Where's my clone?

CDC's new outbreak response network to include Northeastern

EpiPen alternative approval delay highlights citizen petition issue

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

ARCH Venture Partners is raising $3 billion for a life sciences fund

hotspot

knowledge

Sponsor introduction

Featured speakers

Sponsored By

focus

Cancer drug shortages should be causing more outrage

Medicare drug price negotiation’s day in court

Novavax promises a turnaround & Lilly roils the obesity market

Woodcock on FDA’s accelerated approval and her next chapter

Medical leaders decry Supreme Court decision on affirmative action

Covid misinformation case heads to Supreme Court

FDA approval of Sarepta Duchenne genetic therapy gives me hope

ARCH Venture Partners is raising $3 billion for a life sciences fund

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Drug for rare kidney disease narrowly misses mark in clinical trial

explore

Do digital therapeutics have a future in medicine?

Changes to biosimilar regulatory framework must prioritize patients

FDA drug safety: Singulair case shows systemic surveillance flaws

ARCH Venture Partners is raising $3 billion for a life sciences fund

CommonSpirit Health keeps growing, even as it loses money

New Ultima Genomics DNA sequencer can read genome for $100

focus

explore

Wikipedia

leisure time